This article is more than 5 years old. Information may no longer be current.

Opko Health to terminate phase 3 clinical trial of bevasiranib for treating AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MIAMI — Opko Health has decided to terminate its phase 3 trial of bevasiranib for treating wet age-related macular degeneration, the company announced in a press release.

The decision to conclude the clinical program follows a review of preliminary trial data by the Independent Data Monitoring Committee, which found that although bevasiranib showed activity when used in conjunction with Lucentis (ranibizumab, Genentech), the trial was unlikely to meet its primary endpoint, the release said.

"While we are clearly disappointed with the preliminary results of this fully enrolled study, the indications of activity are encouraging, and we look forward to fully analyzing the data in the coming weeks," Phillip Frost, MD, chairman and chief executive officer of Opko Health, said in the release. "We remain committed to the continued development of our siRNA portfolio targeting vascular endothelial growth factor, including our recently announced VEGFA165b sparing siRNA."

The study identified no systemic or ocular safety issues with bevasiranib.